Bioventus Inc. (BVS) Tops Q1 EPS by 5c ; Offers Guidance

Bioventus Inc. (NASDAQ: BVS) reported Q1 EPS of $0.15, $0.05 better than the analyst estimate of $0.10. Revenue for the quarter came in at $132.1 million versus the consensus estimate of $129.86 million.

GUIDANCE:

Bioventus Inc. sees FY2026 EPS of $0.75-$0.79, versus the consensus of $0.75.

For earnings history and earnings-related data on Bioventus Inc. (BVS) click here.

You May Also Be Interested In

• Citi upgrades Bath & Body Works to Buy with $25 price target
• Flexsteel (FLXS) Tops Q4 EPS by 24c, Beats on Revenue; Offers Q1 Revenue Guidance
• Truist Securities Assumes Corcept Therapeutics (CORT) at Buy